Thursday, 21 August 2003
This presentation is part of : Thursday Poster Sessions

PD-027 Efficacy and Safety of Higher Olanzapine Doses in Acutely Agitated Elderly Patients

Donald Hay1, Eva Marquez1, Hillary McGuire1, and Catherine Zofkie2. (1) Neuroscience, Eli Lilly and Company, Indianapolis, IN, USA, (2) Geriatric Care Consultants Inc, Dayton, OH, USA

Objective: Acute agitation sometimes requires higher antipsychotic doses; safety concerns may preclude use in elderly patients. Olanzapine’s efficacy and safety have been reported in general adult populations

Design: We evaluated 2 oral (p.o.) and 4 intramuscular (IM) olanzapine trials in older (>/=50) agitated patients. IM studies used the Positive and Negative Syndrome Scale – Excited Component (PANSS-EC) to measure agitation. Measures varied across oral studies; data were pooled where appropriate. Extrapyramidal symptoms and laboratory tests were evaluated.

Materials and Methods: Patients received olanzapine up to 15 mg/day p.o. and 10 mg/day IM. Numerical baseline-to-endpoint improvement occurred in all studies on all efficacy measures.

Results: Significant improvement was seen at both 2 and 24 hours with 5 mg/day IM (p<.001; p<.001) and 10 mg/day IM (p<.001; p<.001). In oral trials, significant within-group improvement at 1-week was demonstrated with 5 mg/day (p=.003) and sustained through 8-week endpoint (p=.010). Significant baseline-to-endpoint improvement also occurred with 10 mg/day (p=.005) and 15 mg/day (p=.024). No significant adverse events emerged.

Conclusion: Agitation in elderly patients improved on higher olanzapine doses without significant adverse events. Results suggest that doses up to 15 mg/day p.o. or 10 mg/day IM may be used safely in elderly patients. Larger elderly studies are warranted.

Back to PD Thursday Poster Sessions
Back to The Eleventh International Congress